Role of high dose octreotide LAR for the treatment of GEP-NETs

Role of high dose octreotide LAR for the treatment of GEP-NETs

Authors

  • Giulia M. Franchi Dipartimento di Medicina Interna e Specialistica. Unità Funzionale Tumori Endocrini. Istituto Scientifico Universitario San Raffaele
  • Chiara Cappelletti Dipartimento di Medicina Interna e Specialistica. Unità Funzionale Tumori Endocrini. Istituto Scientifico Universitario San Raffaele
  • Valentina V. Villa Dipartimento di Medicina Interna e Specialistica. Unità Funzionale Tumori Endocrini. Istituto Scientifico Universitario San Raffaele
  • Emanuele Bosi Dipartimento di Medicina Interna e Specialistica. Unità Funzionale Tumori Endocrini. Istituto Scientifico Universitario San Raffaele
  • Marco F. Manzoni Dipartimento di Medicina Interna e Specialistica. Unità Funzionale Tumori Endocrini. Istituto Scientifico Universitario San Raffaele

DOI:

https://doi.org/10.7175/cmi.v3i1.555

Keywords:

Gastro-entero-pancreatic neuroendocrine tumours, Somatostatin analogues, High dose octreotide LAR, Medical treatment, Clinical management

Abstract

Neuroendocrine Tumours (NETs) are a heterogeneous group of rare neoplasms that account for 0,5% of all malignancies. The increased incidence observed in the last few decades may be accounted for by increased awareness, improved diagnostic tools and a revision in the definition. The main primary sites are the gastro-entero-pancreatic (GEP) tract (62-67%), and the lung (22-27%). In patients with GEP-NETs, the strongest predictor of 5-years survival is the staging. An adequate clinical management of GEP-NETs should be multidisciplinary and should aim at assuring a good quality of life. Somatostatin (sst) analogues are widely used in these tumours, which often express sst receptors, since they are demonstrated to reduce clinical symptoms and tumour growth. Herein we explore the usefulness of doubling octreotide LAR dose in selected patients after escaping from symptoms control and/or tumour stabilization in course of treatment with standard dose.

Downloads

Published

2009-03-15

Issue

Vol. 3 No. 1 (2009)

Section

Case report

License

Authors who publish with this journal agree to the following terms:
    1. Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution Non-Commercial 4.0 Licence that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
    2. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal. The Publication Agreement can be downloaded here, and should be signed by the Authors and sent to the Publisher when the article has been accepted for publication in this journal.
    3. Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
    4. Authors are permitted to post their work online after publication (the article must link to publisher version, in html format)